<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Am J Med Genet A</journal-id>
<journal-id journal-id-type="iso-abbrev">Am. J. Med. Genet. A</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)1552-4833</journal-id>
<journal-id journal-id-type="publisher-id">AJMG</journal-id>
<journal-title-group>
<journal-title>American Journal of Medical Genetics. Part a</journal-title>
</journal-title-group>
<issn pub-type="ppub">1552-4825</issn>
<issn pub-type="epub">1552-4833</issn>
<publisher>
<publisher-name>John Wiley &amp; Sons, Inc.</publisher-name>
<publisher-loc>Hoboken, USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30919572</article-id>
<article-id pub-id-type="pmc">6916397</article-id>
<article-id pub-id-type="doi">10.1002/ajmg.a.61126</article-id>
<article-id pub-id-type="publisher-id">AJMGA61126</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Original Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinical exome sequencing in 509 Middle Eastern families with suspected Mendelian diseases: The Qatari experience</article-title>
<alt-title alt-title-type="left-running-head">Al‐Dewik et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="ajmga61126-cr-0001">
<name>
<surname>Al‐Dewik</surname>
<given-names>Nader</given-names>
</name>
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-5739-1135</contrib-id>
<xref ref-type="aff" rid="ajmga61126-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="ajmga61126-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ajmga61126-cr-0002">
<name>
<surname>Mohd</surname>
<given-names>Howaida</given-names>
</name>
<xref ref-type="aff" rid="ajmga61126-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ajmga61126-cr-0003">
<name>
<surname>Al‐Mureikhi</surname>
<given-names>Mariam</given-names>
</name>
<xref ref-type="aff" rid="ajmga61126-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ajmga61126-cr-0004">
<name>
<surname>Ali</surname>
<given-names>Rehab</given-names>
</name>
<xref ref-type="aff" rid="ajmga61126-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ajmga61126-cr-0005">
<name>
<surname>Al‐Mesaifri</surname>
<given-names>Fatma</given-names>
</name>
<xref ref-type="aff" rid="ajmga61126-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ajmga61126-cr-0006">
<name>
<surname>Mahmoud</surname>
<given-names>Laila</given-names>
</name>
<xref ref-type="aff" rid="ajmga61126-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ajmga61126-cr-0007">
<name>
<surname>Shahbeck</surname>
<given-names>Noora</given-names>
</name>
<xref ref-type="aff" rid="ajmga61126-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ajmga61126-cr-0008">
<name>
<surname>El‐Akouri</surname>
<given-names>Karen</given-names>
</name>
<xref ref-type="aff" rid="ajmga61126-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ajmga61126-cr-0009">
<name>
<surname>Almulla</surname>
<given-names>Mariam</given-names>
</name>
<xref ref-type="aff" rid="ajmga61126-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ajmga61126-cr-0010">
<name>
<surname>Al Sulaiman</surname>
<given-names>Reem</given-names>
</name>
<xref ref-type="aff" rid="ajmga61126-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ajmga61126-cr-0011">
<name>
<surname>Musa</surname>
<given-names>Sara</given-names>
</name>
<xref ref-type="aff" rid="ajmga61126-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ajmga61126-cr-0012">
<name>
<surname>Al‐Marri</surname>
<given-names>Ajayeb Al‐Nabet</given-names>
</name>
<xref ref-type="aff" rid="ajmga61126-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ajmga61126-cr-0013">
<name>
<surname>Richard</surname>
<given-names>Gabriele</given-names>
</name>
<xref ref-type="aff" rid="ajmga61126-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ajmga61126-cr-0014">
<name>
<surname>Juusola</surname>
<given-names>Jane</given-names>
</name>
<xref ref-type="aff" rid="ajmga61126-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ajmga61126-cr-0015">
<name>
<surname>Solomon</surname>
<given-names>Benjamin D.</given-names>
</name>
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-8826-1023</contrib-id>
<xref ref-type="aff" rid="ajmga61126-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="ajmga61126-cr-0016">
<name>
<surname>Alkuraya</surname>
<given-names>Fowzan S.</given-names>
</name>
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-4158-341X</contrib-id>
<xref ref-type="aff" rid="ajmga61126-aff-0005">
<sup>5</sup>
</xref>
<xref ref-type="aff" rid="ajmga61126-aff-0006">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="ajmga61126-cr-0017">
<name>
<surname>Ben‐Omran</surname>
<given-names>Tawfeg</given-names>
</name>
<xref ref-type="aff" rid="ajmga61126-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="ajmga61126-aff-0007">
<sup>7</sup>
</xref>
<xref ref-type="aff" rid="ajmga61126-aff-0008">
<sup>8</sup>
</xref>
<address>
<email>tawben11@hotmail.com</email>
</address>
</contrib>
</contrib-group>
<aff id="ajmga61126-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Clinical and Metabolic Genetics, Department of Pediatrics</named-content>
<institution>Hamad Medical Corporation</institution>
<city>Doha</city>
<country country="QA">Qatar</country>
</aff>
<aff id="ajmga61126-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">College of Health and Life Sciences</named-content>
<institution>Hamad Bin Khalifa University (HBKU)</institution>
<city>Doha</city>
<country country="QA">Qatar</country>
</aff>
<aff id="ajmga61126-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Laboratory Medicine and Pathology</named-content>
<institution>Hamad Medical Corporation</institution>
<country country="QA">Qatar</country>
</aff>
<aff id="ajmga61126-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Clinical Genomics Program</named-content>
<institution>GeneDx, Inc.</institution>
<city>Gaithersburg</city>
<named-content content-type="country-part">Maryland</named-content>
<country>USA</country>
</aff>
<aff id="ajmga61126-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Department of Genetics, Research Center</named-content>
<institution>King Faisal Specialist Hospital and Research Center</institution>
<city>Riyadh</city>
<country country="SA">Saudi Arabia</country>
</aff>
<aff id="ajmga61126-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Department of Anatomy and Cell Biology</named-content>
<institution>College of Medicine, Alfaisal University</institution>
<city>Riyadh</city>
<country country="SA">Saudi Arabia</country>
</aff>
<aff id="ajmga61126-aff-0007">
<label><sup>7</sup></label>
<named-content content-type="organisation-division">Department of pediatric</named-content>
<institution>Weill Cornell Medical College</institution>
<city>Doha</city>
<country country="QA">Qatar</country>
</aff>
<aff id="ajmga61126-aff-0008">
<label><sup>8</sup></label>
<named-content content-type="organisation-division">Division of Genetic &amp; Genomics Medicine</named-content>
<institution>Sidra Medicine</institution>
<city>Doha</city>
<country country="QA">Qatar</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>
Tawfeg Ben‐Omran, Clinical and Metabolic Genetics, Weill Cornell Medical College, Department of Pediatrics, Hamad Medical Corporation, P. O. BOX. 3050, Doha, Qatar.<break></break>
Email: <email>tawben11@hotmail.com</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>6</month>
<year>2019</year>
</pub-date>
<volume>179</volume>
<issue>6</issue>
<issue-id pub-id-type="doi">10.1002/ajmg.v179.6</issue-id>
<fpage>927</fpage>
<lpage>935</lpage>
<history>
<date date-type="received">
<day>20</day>
<month>10</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>22</day>
<month>1</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>2</month>
<year>2019</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2019 Wiley Periodicals, Inc. <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2019 The Authors. <italic>American Journal of Medical Genetics Part A</italic> published by Wiley Periodicals, Inc.</copyright-statement>
<license license-type="creativeCommonsBy-nc-nd">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:AJMG-179-927.pdf"></self-uri>
<abstract>
<sec id="ajmga61126-sec-0001">
<title>Background</title>
<p>Clinical exome sequencing (CES) is rapidly becoming the diagnostic test of choice in patients with suspected Mendelian diseases especially those that are heterogeneous in etiology and clinical presentation. Reporting large CES series can inform guidelines on best practices for test utilization, and improves accuracy of variant interpretation through clinically‐oriented data sharing.</p>
</sec>
<sec id="ajmga61126-sec-0002">
<title>Methods</title>
<p>This is a retrospective series of 509 probands from Qatar who underwent singleton or trio CES either as a reflex or naïve (first‐tier) test from April 2014 to December 2016 for various clinical indications.</p>
</sec>
<sec id="ajmga61126-sec-0003">
<title>Results</title>
<p>The CES diagnostic yield for the overall cohort was 48.3% (<italic>n</italic> = 246). Dual molecular diagnoses were observed in 2.1% of cases; nearly all of whom (91%) were consanguineous. We report compelling variants in 11 genes with no established Mendelian phenotypes. Unlike reflex‐WES, naïve WES was associated with a significantly shorter diagnostic time (3 months vs. 18 months, <italic>p</italic> &lt; 0.0001).</p>
</sec>
<sec id="ajmga61126-sec-0004">
<title>Conclusion</title>
<p>Middle Eastern patients tend to have a higher yield from CES than outbred populations, which has important implications in test choice especially early in the diagnostic process. The relatively high diagnostic rate is likely related to the predominance of recessive diagnoses (60%) since consanguinity and positive family history were strong predictors of a positive CES.</p>
</sec>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="ajmga61126-kwd-0001">Arab</kwd>
<kwd id="ajmga61126-kwd-0002">clinical exome sequencing</kwd>
<kwd id="ajmga61126-kwd-0003">consanguinity</kwd>
<kwd id="ajmga61126-kwd-0004">Mendelian diseases</kwd>
<kwd id="ajmga61126-kwd-0005">Middle East</kwd>
<kwd id="ajmga61126-kwd-0006">Qatar</kwd>
</kwd-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="9"></table-count>
<page-count count="9"></page-count>
<word-count count="5489"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>June 2019</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.3 mode:remove_FC converted:17.12.2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="ajmga61126-cit-9001" publication-type="journal">
<string-name>
<surname>Al‐Dewik</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Mohd</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Al‐Mureikhi</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Clinical exome sequencing in 509 Middle Eastern families with suspected Mendelian diseases: The Qatari experience</article-title>. <source xml:lang="en"/>Am J Med Genet Part A. <year>2019</year>;<volume>179A</volume>:<fpage>927</fpage>–<lpage>935</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.61126</pub-id>
</mixed-citation>
</p>
</notes>
</front>
<body id="ajmga61126-body-0001">
<sec id="ajmga61126-sec-0005">
<label>1</label>
<title>INTRODUCTION</title>
<p>Genetic heterogeneity, phenotypic variability, and disease rarity (with consequent lack of familiarity) are all factors that make the traditional diagnostic approach to genetic disorders, whereby a specific gene is selected for sequencing based on the clinical phenotype, very challenging. Whole exome sequencing, with its ability to interrogate many genes in both hypothesis‐driven and hypothesis‐free approaches, has revolutionized the diagnostic process, and clinical exome sequencing (CES) is now a widely adopted diagnostic test. For the purposes of manuscript terminology, CES can be performed as a first‐tier test without performing any prior diagnostic workup, which is commonly, referred to as a “naïve” CES. It can also be performed as a “reflex” CES following prior inconclusive diagnostic workup consisting of imaging studies and/or laboratory studies and/or other genetic tests (whole genome array CGH, single gene testing or NGS multigene panels).</p>
<p>The diagnostic yield of CES, commonly estimated at ~25%, is high compared to other diagnostic tools, including molecular karyotyping, which is officially endorsed by professional societies as a first‐tier test in patients with developmental delay and those with congenital anomalies. Although CES has not yet been endorsed by professional societies as a first‐tier test for patients with suspected Mendelian disorders, recent studies support such an indication for CES and suggest that earlier CES is associated with more favorable cost/benefit ratio (Stark et al., <xref ref-type="ref" rid="ajmga61126-bib-0013">2018</xref>).</p>
<p>In 2015, we reported a high diagnostic yield of CES based on our local experience with the first 149 patients undergoing this testing (Yavarna et al., <xref ref-type="ref" rid="ajmga61126-bib-0015">2015</xref>). The relatively high diagnostic yield appeared to correlate with the frequency of homozygous recessive etiologies, which accounted for the majority of cases. This is not surprising since the Middle Eastern population is characterized by a high level of consanguinity, which was found to strongly predict a positive CES result in that study. Since that study, several others have confirmed a relatively high molecular diagnostic yield of CES in Middle‐Eastern families (Alfares et al., <xref ref-type="ref" rid="ajmga61126-bib-0001">2017</xref>; Al‐Shamsi, Hertecant, Souid, &amp; Al‐Jasmi, <xref ref-type="ref" rid="ajmga61126-bib-0003">2016</xref>; Anazi et al., <xref ref-type="ref" rid="ajmga61126-bib-0004">2017</xref>; Charng et al., <xref ref-type="ref" rid="ajmga61126-bib-0005">2016</xref>; Fattahi et al., <xref ref-type="ref" rid="ajmga61126-bib-0007">2016</xref>; Monies et al., <xref ref-type="ref" rid="ajmga61126-bib-0009">2017</xref>). In this follow‐up study, we expand the reporting of CES from more than 500 previously unpublished cases. In addition to confirming the trends observed in the smaller cohort, the large size of this cohort allowed us to report substantially more novel variants, including those in genes that we propose as novel candidate genes. Our expanded cohort also allowed us to observe the time‐saving advantage of “naïve” versus “reflex” CES.</p>
</sec>
<sec id="ajmga61126-sec-0006">
<label>2</label>
<title>PATIENTS AND METHODS</title>
<sec id="ajmga61126-sec-0007">
<label>2.1</label>
<title>Patients</title>
<p>This study includes patients referred to the Clinical and Metabolic Genetics, Pediatrics Department at Hamad Medical Corporation (HMC) from April 2014 to December 2016. Patients were referred for a variety of reasons, including neurocognitive/neurodevelopmental or neuromuscular disorders, multiple congenital anomalies or disorders of other organ systems, such as immunologic, endocrine, or cardiac disorders (described below and in Table <xref ref-type="table" rid="ajmga61126-tbl-0002">2</xref>). Among the 509 patients, 359 underwent CES as a first‐tier test (naïve CES), while 150 patients had a prior diagnostic workup with imaging and/or laboratory studies, including other genetic tests such as whole genome array CGH, single gene testing or NGS multigene panels, which did not establish a diagnosis (reflex CES).</p>
<p>Patients received pre‐ and post‐test counseling about the scope of CES and its potential to reveal information unrelated to their original disease; informed consent was obtained from all patients or guardians by local clinicians. Peripheral blood samples from patients and their parents were obtained for CES as available. Detailed clinical data including medical history, family pedigree, thorough physical and dysmorphology examination, and any clinically indicated tests, such as MRI or genetic/metabolic were collected. The CES was performed as a part of the diagnostic work up and standard of care. In the case of an inconclusive CES, reanalysis of CES was done at least 1 year after the date of completion of the original CES. This study was approved by the local IRB (Study protocol no: MRC‐01‐18‐273). The “solved” cases in our study were determined to be diagnostic based on molecular results of CES and reanalysis of CES and clinical correlation by a group of expert clinical geneticists, genetic counselors and clinical laboratory scientists.</p>
</sec>
<sec id="ajmga61126-sec-0008">
<label>2.2</label>
<title>CES and variant calling</title>
<p>DNA extracted from peripheral blood samples was sent to a molecular diagnostic laboratory and CES, bioinformatics analysis and variant confirmation and interpretation were performed as reported earlier; when ordered based on clinical indication, mitochondrial testing was performed via a separate mitochondrial genome sequencing and deletion testing assay, with final CES and mitochondrial results returned as a single, combined report (Yavarna et al., <xref ref-type="ref" rid="ajmga61126-bib-0015">2015</xref>). Briefly, all variants were classified according to the ACMG guidelines (Richards et al., <xref ref-type="ref" rid="ajmga61126-bib-1011">2015</xref>). To score variants for the allele frequency criteria in the guidelines, gnomAD and the GME databases were used. A proprietary method for copy number variant (CNV) analysis was used (Retterer et al., <xref ref-type="ref" rid="ajmga61126-bib-0011">2015</xref>). All reported CNVs, as well as other clinically reported variants, were orthogonally confirmed using an appropriate secondary method, such as exon‐level array CGH microarray.</p>
</sec>
<sec id="ajmga61126-sec-0009">
<label>2.3</label>
<title>Statistical analysis</title>
<p>The significance of the diagnostic rate of trio‐CES versus singleton‐CES, <italic>p</italic> values was calculated by 1‐tailed Fisher exact test. A <italic>p</italic> value of 0.05 was used as a significance threshold. Odds ratio and 95% confidence interval (CI) for the significance of difference in diagnostic rate were also calculated using SPSS.</p>
</sec>
</sec>
<sec id="ajmga61126-sec-0010">
<label>3</label>
<title>RESULTS</title>
<sec id="ajmga61126-sec-0011">
<label>3.1</label>
<title>Patient demographics</title>
<p>A total of 509 patients who presented with rare and diverse genetic disorders underwent CES. The male to female ratio was 1:1 (Female: <italic>N</italic> = 248, 49%; Male: <italic>N</italic> = 261, 51%). Patient ages ranged from prenatal to 53 years. Out of the 509 patients, 467 patients (92%) were children (18 years or younger); 265 (52%) were children younger than 5 years at the time of testing.</p>
<p>Trio (child‐parents) or quad (child, sibling, parents) analysis was used for CES in 34% of cases (159/467) in the child‐proband group, more than in the adult group (8/42 patients; 19%) (Odds ratio: 2.2 [95% CI, 0.99–4.8], <italic>p</italic> &lt; 0.03), reflecting limited parental availability for adult patients. Males were slightly overrepresented in the childhood group (male: 252 of 467 patients, 54%; female: 215 of 467 patients, 46%; Odds ratio: 1.37 [95% CI, 1.0–1.7], <italic>p</italic> &lt; 0.01) while the opposite was observed in the adult group (men: 9 of 42 patients, 21%; women: 33 of 42 patients, 79%; Odds ratio: 3.86 [95% CI, 1.887–7.901, <italic>p</italic> &lt; 0.01]). Consanguinity or a positive family history was observed or reported in 65.0% and 32.0% of cases, respectively. The backgrounds of the probands included nationals from Qatar (58.0%), other Arab countries (27.0%) and the Indian subcontinent (15.0%; Table <xref ref-type="table" rid="ajmga61126-tbl-0001">1</xref>).</p>
<table-wrap id="ajmga61126-tbl-0001" orientation="portrait" position="float" xml:lang="en">
<label>Table 1</label>
<caption>
<p>Patient demographics for 509 cases</p>
</caption>
<table frame="hsides" rules="cols">
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="char" char="(" span="1"/>
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="bottom">Group</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Sub‐group</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Number (%)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">Gender</td>
<td align="left" colspan="1" rowspan="1" valign="top">Male</td>
<td align="char" colspan="1" rowspan="1" valign="top">261 (51%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Female</td>
<td align="char" colspan="1" rowspan="1" valign="top">248 (49%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="3" valign="top">Age</td>
<td align="left" colspan="1" rowspan="1" valign="top">0 ≤ 5 years</td>
<td align="char" colspan="1" rowspan="1" valign="top">265 (52%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">5 ≤ 18 years</td>
<td align="char" colspan="1" rowspan="1" valign="top">202 (40%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">&gt;18 years</td>
<td align="char" colspan="1" rowspan="1" valign="top">42 (8%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="3" valign="top">Nationality</td>
<td align="left" colspan="1" rowspan="1" valign="top">Qatari</td>
<td align="char" colspan="1" rowspan="1" valign="top">294 (58%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Other Arab countries</td>
<td align="char" colspan="1" rowspan="1" valign="top">139 (27%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Indian subcontinent</td>
<td align="char" colspan="1" rowspan="1" valign="top">76 (15%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">Parental consanguinity</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
<td align="char" colspan="1" rowspan="1" valign="top">332 (65%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">No</td>
<td align="char" colspan="1" rowspan="1" valign="top">177 (35%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">Family history</td>
<td align="left" colspan="1" rowspan="1" valign="top">Positive</td>
<td align="char" colspan="1" rowspan="1" valign="top">162 (32%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Negative</td>
<td align="char" colspan="1" rowspan="1" valign="top">347 (68%)</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="ajmga61126-sec-0012">
<label>3.2</label>
<title>Patients and their clinical presentations</title>
<p>Patients presented with diverse clinical phenotypes: 229 (45.0%) had neurocognitive (NC), 45 (9.0%) neuromuscular (NM) disorders, 116 (23.0%) multiple congenital anomalies (MCAs), and 119 (23.0%) had other system manifestations (OSMs), such as endocrine, GI, or immunologic features (Table <xref ref-type="table" rid="ajmga61126-tbl-0002">2</xref>). The clinical presentation in several patients showed atypical phenotype meaning that the clinical presentation deviates from the established gene‐linked phenotype as summarized in (Supporting Information Table <xref ref-type="supplementary-material" rid="ajmga61126-supitem-0001">S6</xref>).</p>
<table-wrap id="ajmga61126-tbl-0002" orientation="portrait" position="float" xml:lang="en">
<label>Table 2</label>
<caption>
<p>Distribution of diagnostic cases according to clinical presentations</p>
</caption>
<table frame="hsides" rules="cols">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">Categories</th>
<th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">Total number (%)</th>
<th align="left" colspan="1" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">Total number of positive cases (%)</th>
<th align="left" colspan="1" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">Singleton CES</th>
<th align="left" colspan="1" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">Trio and Quad CES</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="bottom">Neurocognitive (NC) disorders</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">229</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">45.0%</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">106 (46.0%)</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">63</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">43</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Neuromuscular (NM) disorders</td>
<td align="char" colspan="1" rowspan="1" valign="top">45</td>
<td align="left" colspan="1" rowspan="1" valign="top">9.0%</td>
<td align="left" colspan="1" rowspan="1" valign="top">29 (64.4%)</td>
<td align="char" colspan="1" rowspan="1" valign="top">15</td>
<td align="char" colspan="1" rowspan="1" valign="top">14</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Multiple congenital anomalies (MCAs)</td>
<td align="char" colspan="1" rowspan="1" valign="top">116</td>
<td align="left" colspan="1" rowspan="1" valign="top">23.0%</td>
<td align="left" colspan="1" rowspan="1" valign="top">45 (38.8%)</td>
<td align="char" colspan="1" rowspan="1" valign="top">32</td>
<td align="char" colspan="1" rowspan="1" valign="top">13</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Other system manifestations (OSMs)<xref ref-type="fn" rid="ajmga61126-note-0001">a</xref>
</td>
<td align="char" colspan="1" rowspan="1" valign="top">119</td>
<td align="left" colspan="1" rowspan="1" valign="top">23.0%</td>
<td align="left" colspan="1" rowspan="1" valign="top">66<xref ref-type="fn" rid="ajmga61126-note-0001">a</xref> (55.5%)</td>
<td align="char" colspan="1" rowspan="1" valign="top">44</td>
<td align="char" colspan="1" rowspan="1" valign="top">22</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Total</td>
<td align="char" colspan="1" rowspan="1" valign="top">509</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">246 (48.3%)</td>
<td align="char" colspan="1" rowspan="1" valign="top">154</td>
<td align="char" colspan="1" rowspan="1" valign="top">92</td>
</tr>
</tbody>
</table>
<table-wrap-foot id="ajmga61126-ntgp-0001">
<fn id="ajmga61126-note-0001">
<label>a</label>
<p>Ten cases of each Endocrine and GI, and four cases of each nephrology, ophthalmology, Immunology, metabolic, pulmonology, rheumatology, dermatology, neurology.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="ajmga61126-sec-0013">
<label>3.3</label>
<title>Diagnostic yield of CES</title>
<p>The overall diagnostic yield by the CES in this study was 48.3% (<italic>n</italic> = 246), (naive 48.0%, <italic>n</italic> = 173/359 vs. reflex CES 48.6%, <italic>n</italic> = 73/150). The molecular diagnostic rate for each of the phenotypic groups described above is shown in Table <xref ref-type="table" rid="ajmga61126-tbl-0002">2</xref>.</p>
<p>The solved cases (diagnostic yield) were stratified according to the major clinical phenotypes, NC: 106 (46.0%); NM: 29 (64.4%); MCAs: 45 (38.8%); OSMs: 66 (55.5%; Table <xref ref-type="table" rid="ajmga61126-tbl-0002">2</xref>).</p>
<p>The overall diagnostic yield for children younger than 5 years was 132/265 (49.0%). Of the children younger than 5 years at the time of testing (<italic>n</italic> = 265), trio‐CES was performed for 32% (<italic>n</italic> = 87) of cases, and singleton‐CES for 68% (<italic>n</italic> = 178) cases, respectively. The diagnostic yield of trio‐CES was 53% (46/87), which was higher than for singleton‐CES (85/177; 48%). The parental consanguinity in this group was 96/132 cases (72%).</p>
<p>The overall diagnostic yield for children aged 5–18 years was 47% (96/202). Out of the total number children aged 5–18 years (<italic>n</italic> = 202), trio‐CES and singleton‐CES were performed for 72 (35.0%) and 130 (65%) of cases, respectively. The diagnostic rate for trio‐CES (43/72 cases; 59.0%) was significantly higher compared to singleton‐CES (53/130 cases; 40.0%) (Odds ratio: 2.15 [95% CI, 1.2–3.9], <italic>p</italic> &lt; 0.01) (Table <xref ref-type="table" rid="ajmga61126-tbl-0003">3</xref>). The parental consanguinity in this group was 62/97 cases (65%). The presence of consanguinity and positive family history predicted a higher clinical sensitivity (56.3%) as compared with those who lacked both (37.0%; <italic>p</italic> = 0.02). (Table <xref ref-type="table" rid="ajmga61126-tbl-0004">4</xref>).</p>
<table-wrap id="ajmga61126-tbl-0003" orientation="portrait" position="float" xml:lang="en">
<label>Table 3</label>
<caption>
<p>Molecular diagnosis rate of phenotypic subgroups by age group</p>
</caption>
<table frame="hsides" rules="cols">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="3" style="border-bottom:solid 1px #000000" valign="bottom">Categories</th>
<th align="left" colspan="9" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">Age groups</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="3" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">≤5 years</th>
<th align="left" colspan="3" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">5 ≤ 18 years</th>
<th align="left" colspan="1" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom"></th>
<th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="bottom">&gt;18 years</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="bottom">Total no</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Singleton</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Trio</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Total no</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Singleton</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Trio and</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Total no</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Singleton</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Trio and</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Neurocognitive (NC) only</bold>
</td>
<td align="char" colspan="1" rowspan="1" valign="top">59</td>
<td align="char" colspan="1" rowspan="1" valign="top">37</td>
<td align="char" colspan="1" rowspan="1" valign="top">22</td>
<td align="char" colspan="1" rowspan="1" valign="top">45</td>
<td align="char" colspan="1" rowspan="1" valign="top">24</td>
<td align="char" colspan="1" rowspan="1" valign="top">21</td>
<td align="char" colspan="1" rowspan="1" valign="top">2</td>
<td align="char" colspan="1" rowspan="1" valign="top">2</td>
<td align="char" colspan="1" rowspan="1" valign="top">0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Neuromuscular (NM) only</bold>
</td>
<td align="char" colspan="1" rowspan="1" valign="top">12</td>
<td align="char" colspan="1" rowspan="1" valign="top">6</td>
<td align="char" colspan="1" rowspan="1" valign="top">6</td>
<td align="char" colspan="1" rowspan="1" valign="top">16</td>
<td align="char" colspan="1" rowspan="1" valign="top">9</td>
<td align="char" colspan="1" rowspan="1" valign="top">7</td>
<td align="char" colspan="1" rowspan="1" valign="top">2</td>
<td align="char" colspan="1" rowspan="1" valign="top">1</td>
<td align="char" colspan="1" rowspan="1" valign="top">1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Multiple congenital anomalies (MCA)</bold>
</td>
<td align="char" colspan="1" rowspan="1" valign="top">29</td>
<td align="char" colspan="1" rowspan="1" valign="top">22</td>
<td align="char" colspan="1" rowspan="1" valign="top">7</td>
<td align="char" colspan="1" rowspan="1" valign="top">12</td>
<td align="char" colspan="1" rowspan="1" valign="top">6</td>
<td align="char" colspan="1" rowspan="1" valign="top">6</td>
<td align="char" colspan="1" rowspan="1" valign="top">4</td>
<td align="char" colspan="1" rowspan="1" valign="top">4</td>
<td align="char" colspan="1" rowspan="1" valign="top">0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Other system manifestations</bold>
</td>
<td align="char" colspan="1" rowspan="1" valign="top">32</td>
<td align="char" colspan="1" rowspan="1" valign="top">20</td>
<td align="char" colspan="1" rowspan="1" valign="top">12</td>
<td align="char" colspan="1" rowspan="1" valign="top">23</td>
<td align="char" colspan="1" rowspan="1" valign="top">14</td>
<td align="char" colspan="1" rowspan="1" valign="top">9</td>
<td align="char" colspan="1" rowspan="1" valign="top">10</td>
<td align="char" colspan="1" rowspan="1" valign="top">9</td>
<td align="char" colspan="1" rowspan="1" valign="top">1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Total</bold>
</td>
<td align="char" colspan="1" rowspan="1" valign="top">132</td>
<td align="char" colspan="1" rowspan="1" valign="top">85</td>
<td align="char" colspan="1" rowspan="1" valign="top">47</td>
<td align="char" colspan="1" rowspan="1" valign="top">96</td>
<td align="char" colspan="1" rowspan="1" valign="top">53</td>
<td align="char" colspan="1" rowspan="1" valign="top">43</td>
<td align="char" colspan="1" rowspan="1" valign="top">18</td>
<td align="char" colspan="1" rowspan="1" valign="top">16</td>
<td align="char" colspan="1" rowspan="1" valign="top">2</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="ajmga61126-tbl-0004" orientation="portrait" position="float" xml:lang="en">
<label>Table 4</label>
<caption>
<p>Distribution of cases for parental consanguinity and family history</p>
</caption>
<table frame="hsides" rules="groups">
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" valign="bottom">Group</th>
<th align="left" colspan="2" rowspan="1" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" valign="bottom">Parental consanguinity (PC)</th>
<th align="left" colspan="2" rowspan="1" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" valign="bottom">Family history (FH)</th>
<th align="left" colspan="2" rowspan="1" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" valign="bottom">Parental consanguinity and family history</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="bottom">Classification</th>
<th align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="bottom">Yes</th>
<th align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="bottom">No</th>
<th align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="bottom">Yes</th>
<th align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="bottom">No</th>
<th align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="bottom">Yes/positive</th>
<th align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="bottom">No/negative</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">Total no</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">332</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">177</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">162</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">347</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">119</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">135</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">Solved</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">174 (52.4%)</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">70 (39.5%)</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">88 (54.3%)</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">156 (44.9%)</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">67 (56.3%)</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">50 (37.0%)</td>
</tr>
<tr style="border-bottom:solid 1px #000000">
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top"></td>
<td align="left" colspan="2" rowspan="1" style="border-right:solid 1px #000000" valign="top">Odds ratio: 1.68 (95% CI, 1.2–2.4) <italic>p</italic> = 0.003</td>
<td align="left" colspan="2" rowspan="1" style="border-right:solid 1px #000000" valign="top">Odds ratio: 1.45 (95% CI, 1.0–2.1) <italic>p</italic> = 0.03</td>
<td align="left" colspan="2" rowspan="1" style="border-right:solid 1px #000000" valign="top">Odds ratio: 2.19 (95% CI, 1.3–3.6) <italic>p</italic> = 0.01</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="ajmga61126-sec-0014">
<label>3.4</label>
<title>Characterization of CES molecular findings</title>
<p>Using CES, we identified 176 novel and 62 previously published pathogenic or likely pathogenic single nucleotide variants in known genes linked to the clinical phenotypes (Table <xref ref-type="table" rid="ajmga61126-tbl-0005">5</xref>, Supporting Information Tables <xref ref-type="supplementary-material" rid="ajmga61126-supitem-0001">S1</xref>–<xref ref-type="supplementary-material" rid="ajmga61126-supitem-0001">S3</xref>). More than half of the reported PV were homozygous variants in AR genes (60.0%) consistent with the high rate of consanguinity in the study population. Nevertheless, a considerable number of patients had PVs in AD (33%) or X‐linked genes (5%), or de novo CNVs (2%) (Figure <xref ref-type="fig" rid="ajmga61126-fig-0001">1</xref>).</p>
<table-wrap id="ajmga61126-tbl-0005" orientation="portrait" position="float" xml:lang="en">
<label>Table 5</label>
<caption>
<p>Mutation analysis in diagnostic cases</p>
</caption>
<table frame="hsides" rules="groups">
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="bottom">Group</th>
<th align="left" colspan="5" rowspan="1" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" valign="bottom">Gene</th>
</tr>
</thead>
<tbody valign="top">
<tr style="border-bottom:solid 1px #000000">
<td align="left" colspan="1" rowspan="2" style="border-right:solid 1px #000000" valign="top">Novel, likely pathogenic variants in known disease genes</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">Autosomal recessive (AR)</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">Autosomal dominant (AD)</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top"></td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">Semi dominant</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">X‐linked</td>
</tr>
<tr style="border-bottom:solid 1px #000000">
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">
<p>
<italic>PIEZO1x3</italic>
</p>
<p>
<italic>LRP5</italic>
</p>
<p>
<italic>PTH</italic>
</p>
<p>
<italic>GJC2</italic>
</p>
<p>
<italic>ELOVL4</italic>
</p>
<p>
<italic>EDNRB</italic>
</p>
<p>
<italic>COL7A1</italic>
</p>
<p>
<italic>CHRNAx2</italic>
</p>
<p>
<italic>ANK3</italic>
</p>
<p>
<italic>CUL7</italic>
</p>
<p>
<italic>AIPL1</italic>
</p>
<p>
<italic>ALDH7A1</italic>
</p>
<p>
<italic>DAG1</italic>
</p>
<p>
<italic>ACY1</italic>
</p>
<p>
<italic>CNTNAP1</italic>
</p>
<p>
<italic>B3GALNT2 x2</italic>
</p>
<p>
<italic>OCLN</italic>
</p>
<p>
<italic>CENPF x2</italic>
</p>
<p>
<italic>LONP1</italic>
</p>
<p>
<italic>VPS13B</italic>
</p>
<p>
<italic>LRBA</italic>
</p>
<p>
<italic>GFPT1</italic>
</p>
<p>
<italic>GLE1</italic>
</p>
<p>
<italic>CWF19L1x3</italic>
</p>
<p>
<italic>XYLT1</italic>
</p>
<p>
<italic>ECEL1</italic>
</p>
<p>
<italic>ATP6V0A4</italic>
</p>
<p>
<italic>SLC6A3x2</italic>
</p>
<p>
<italic>DYM</italic>
</p>
<p>
<italic>EIF2B2</italic>
</p>
<p>
<italic>SLC2A2</italic>
</p>
<p>
<italic>FKTN</italic>
</p>
<p>
<italic>FBP1</italic>
</p>
<p>
<italic>GCLC</italic>
</p>
<p>
<italic>PHKB</italic>
</p>
<p>
<italic>NBEAL2</italic>
</p>
<p>
<italic>RAB27A</italic>
</p>
<p>
<italic>SLC46A1</italic>
</p>
<p>
<italic>HPS1x2</italic>
</p>
<p>
<italic>HPS5</italic>
</p>
<p>
<italic>SLC25A15</italic>
</p>
<p>
<italic>IGHMBP2</italic>
</p>
<p>
<italic>ITPA</italic>
</p>
<p>
<italic>CC2D2Ax2</italic>
</p>
<p>
<italic>KCTD7</italic>
</p>
<p>
<italic>LIPH</italic>
</p>
<p>
<italic>MED17</italic>
</p>
<p>
<italic>MICU1x7</italic>
</p>
<p>
<italic>ATPAF2</italic>
</p>
<p>
<italic>RRM2B</italic>
</p>
<p>
<italic>GNPTG</italic>
</p>
<p>
<italic>MYBPC3</italic>
</p>
<p>
<italic>KLHL41</italic>
</p>
<p>
<italic>NEBx3</italic>
</p>
<p>
<italic>NHEJ1</italic>
</p>
<p>
<italic>NPC1</italic>
</p>
<p>
<italic>PDE6C</italic>
</p>
<p>
<italic>PEX2</italic>
</p>
<p>
<italic>PGAP3</italic>
</p>
<p>
<italic>PLEC</italic>
</p>
<p>
<italic>POMT1</italic>
</p>
<p>
<italic>LAMA1</italic>
</p>
<p>
<italic>SLC10A2x2</italic>
</p>
<p>
<italic>DNAH5</italic>
</p>
<p>
<italic>DNAH11</italic>
</p>
<p>
<italic>ASPM</italic>
</p>
<p>
<italic>RYR1</italic>
</p>
<p>
<italic>LIFR</italic>
</p>
<p>
<italic>TCTN3</italic>
</p>
<p>
<italic>TMPRSS4x2</italic>
</p>
<p>
<italic>CYP2R1</italic>
</p>
<p>
<italic>CYP2R1</italic>
</p>
<p>
<italic>EIF2AK3</italic>
</p>
<p>
<italic>WWOX</italic>
</p>
<p>
<italic>POLH</italic>
</p>
<p>
<italic>TBCD</italic>
</p>
<p>
<italic>PEX13</italic>
</p>
<p>
<italic>RPIA x2</italic>
</p>
<p>
<italic>FANCA</italic>
</p>
<p>
<italic>FBXL4</italic>
</p>
<p>
<italic>SPTA1</italic>
</p>
</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">
<p>
<italic>ACTA1</italic>
</p>
<p>
<italic>SLC4A1</italic>
</p>
<p>
<italic>PLA2G7</italic>
</p>
<p>
<italic>KIF1A</italic>
</p>
<p>
<italic>EVC</italic>
</p>
<p>
<italic>DES</italic>
</p>
<p>
<italic>COL6A1</italic>
</p>
<p>
<italic>ABCB4</italic>
</p>
<p>
<italic>BSCL2</italic>
</p>
<p>
<italic>ANKRD11</italic>
</p>
<p>
<italic>ASXL3</italic>
</p>
<p>
<italic>BRAF</italic>
</p>
<p>
<italic>CAMTA1</italic>
</p>
<p>
<italic>CHD2</italic>
</p>
<p>
<italic>ARID1Bx2</italic>
</p>
<p>
<italic>COL11A1</italic>
</p>
<p>
<italic>TBX18</italic>
</p>
<p>
<italic>RAD21</italic>
</p>
<p>
<italic>DSG2</italic>
</p>
<p>
<italic>DYNC1H1x2 COL5A2</italic>
</p>
<p>
<italic>COL3A1</italic>
</p>
<p>
<italic>SLC1A3</italic>
</p>
<p>
<italic>LDLR</italic>
</p>
<p>
<italic>FGFR2</italic>
</p>
<p>
<italic>FOXP2</italic>
</p>
<p>
<italic>GATAD2B</italic>
</p>
<p>
<italic>GRIN2Ax2</italic>
</p>
<p>
<italic>HNRNPU</italic>
</p>
<p>
<italic>KMT2D</italic>
</p>
<p>
<italic>KAT6Bx2</italic>
</p>
<p>
<italic>KCNT1x2</italic>
</p>
<p>
<italic>LDB3</italic>
</p>
<p>
<italic>EFTUD2</italic>
</p>
<p>
<italic>MED13Lx2</italic>
</p>
<p>
<italic>MEF2Cx2</italic>
</p>
<p>
<italic>AHDC1</italic>
</p>
<p>
<italic>NF1</italic>
</p>
<p>
<italic>NOTCH1</italic>
</p>
<p>
<italic>COL1A1</italic>
</p>
<p>
<italic>PIEZO1</italic>
</p>
<p>
<italic>PIK3CD</italic>
</p>
<p>
<italic>PIK3R1</italic>
</p>
<p>
<italic>POGZ</italic>
</p>
<p>
<italic>PURA</italic>
</p>
<p>
<italic>RUNX2</italic>
</p>
<p>
<italic>SALL4</italic>
</p>
<p>
<italic>SCN2A</italic>
</p>
<p>
<italic>SETD2</italic>
</p>
<p>
<italic>SHANK3</italic>
</p>
<p>
<italic>SLC9A9</italic>
</p>
<p>
<italic>ATL1</italic>
</p>
<p>
<italic>SPECC1L</italic>
</p>
<p>
<italic>DNMT3A</italic>
</p>
<p>
<italic>TP63</italic>
</p>
<p>
<italic>TCOF1</italic>
</p>
</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top"></td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">
<italic>OPA1</italic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">
<p>
<italic>COL4A5</italic>
</p>
<p>
<italic>ATRX</italic>
</p>
<p>
<italic>DDX3X</italic>
</p>
<p>
<italic>USP35</italic>
</p>
<p>
<italic>HUWE1x2</italic>
</p>
<p>
<italic>KDM5C</italic>
</p>
<p>
<italic>KIAA2022</italic>
</p>
<p>
<italic>PDHA1x2</italic>
</p>
<p>
<italic>TAF1</italic>
</p>
</td>
</tr>
<tr style="border-bottom:solid 1px #000000">
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">Variants in novel candidate genes</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">
<p>
<italic>HSPB11</italic>
</p>
<p>
<italic>CDK9 x2</italic>
</p>
<p>
<italic>KIAA0195</italic>
</p>
<p>
<italic>UNC13A</italic>
</p>
<p>
<italic>TRAF3IP2</italic>
</p>
<p>
<italic>LAMTOR4</italic>
</p>
<p>
<italic>SCHIP1</italic> and <italic>IQCJ‐SCHIP1</italic>
</p>
<p>
<italic>MAP4K4</italic>
</p>
</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">
<p>
<italic>TUBA3E</italic>
</p>
<p>
<italic>CLCN3</italic>
</p>
<p>
<italic>GRM5</italic>
</p>
<p>
<italic>XPOT</italic>
</p>
<p>
<italic>GALNT11</italic>
</p>
</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top"></td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top"></td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top"></td>
</tr>
<tr style="border-bottom:solid 1px #000000">
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">Previously reported P/LP variants in known disease genes</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">
<p>
<italic>SIX6</italic>
</p>
<p>
<italic>MYL2</italic>
</p>
<p>
<italic>COL7A1</italic>
</p>
<p>
<italic>CC2D2Ax2</italic>
</p>
<p>
<italic>TMIE</italic>
</p>
<p>
<italic>VPS13B</italic>
</p>
<p>
<italic>SRD5A3</italic>
</p>
<p>
<italic>MCEE</italic>
</p>
<p>
<italic>LAMA2 x2</italic>
</p>
<p>
<italic>PCNT</italic>
</p>
<p>
<italic>DDCx2</italic>
</p>
<p>
<italic>PLA2G6</italic>
</p>
<p>
<italic>ISCA2</italic>
</p>
<p>
<italic>UQCRQ</italic>
</p>
<p>
<italic>C12orf57</italic>
</p>
<p>
<italic>RSPH9</italic>
</p>
<p>
<italic>SNX14</italic>
</p>
<p>
<italic>SEPN1</italic>
</p>
<p>
<italic>CLCN1</italic>
</p>
<p>
<italic>MKKS</italic>
</p>
<p>
<italic>ABCB4</italic>
</p>
<p>
<italic>SEPSECS</italic>
</p>
<p>
<italic>XYLT1</italic>
</p>
<p>
<italic>SGCA</italic>
</p>
<p>
<italic>OTOF</italic>
</p>
<p>
<italic>RNASEH2C</italic>
</p>
<p>
<italic>BCS1L</italic>
</p>
<p>
<italic>SLC24A5</italic>
</p>
<p>
<italic>TMPRSS3</italic>
</p>
<p>
<italic>PEX1</italic>
</p>
<p>
<italic>PEX5</italic>
</p>
<p>
<italic>GALC</italic>
</p>
<p>
<italic>TRAPPC9</italic>
</p>
</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">
<p>
<italic>TCOF1</italic>
</p>
<p>
<italic>SMARCB1</italic>
</p>
<p>
<italic>SYNGAP1</italic>
</p>
<p>
<italic>MBD5</italic>
</p>
<p>
<italic>MYH3</italic>
</p>
<p>
<italic>PTPN11x3</italic>
</p>
<p>
<italic>TP53</italic>
</p>
<p>
<italic>RYR1</italic>
</p>
<p>
<italic>LDB3</italic>
</p>
<p>
<italic>TPM2</italic>
</p>
<p>
<italic>MAP2K1</italic>
</p>
<p>
<italic>CSNK2A1</italic>
</p>
<p>
<italic>FLG</italic>
</p>
<p>
<italic>SATB2</italic>
</p>
<p>
<italic>TRPV4</italic>
</p>
<p>
<italic>NSD1</italic>
</p>
<p>
<italic>FGFR2</italic>
</p>
<p>
<italic>TNNI2</italic>
</p>
<p>
<italic>MYL2</italic>
</p>
<p>
<italic>TBCD</italic>
</p>
<p>
<italic>PPP2R5C</italic>
</p>
<p>
<italic>CDK13</italic>
</p>
</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top"></td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">
<italic>LDLR</italic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">
<p>
<italic>FOXP3</italic>
</p>
<p>
<italic>MECP2</italic>
</p>
<p>
<italic>MECP2</italic>
</p>
<p>
<italic>MECP2</italic>
</p>
<p>
<italic>CLCN4</italic>
</p>
</td>
</tr>
<tr style="border-bottom:solid 1px #000000">
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">Novel copy number variants</td>
<td align="left" colspan="5" rowspan="1" style="border-right:solid 1px #000000" valign="top">
<list id="ajmga61126-list-0001" list-type="bullet"><list-item id="ajmga61126-li-0001"><p>
<italic>KPTN</italic> deletion (exons 9–12)</p></list-item><list-item id="ajmga61126-li-0002"><p>2.9 Mb deletion in 15q15.3–15q21.1</p></list-item><list-item id="ajmga61126-li-0003"><p>1.3 kb deletion in 5q12.1</p></list-item><list-item id="ajmga61126-li-0004"><p>283 kb duplication in 16p11.2</p></list-item><list-item id="ajmga61126-li-0005"><p>De novo 361 Mb duplication of 17p13.3</p></list-item><list-item id="ajmga61126-li-0006"><p>Partial gene duplication in <italic>DNAH5</italic>
</p></list-item><list-item id="ajmga61126-li-0007"><p>Partial gene duplication involving <italic>MICU1</italic>
</p></list-item></list>
</td>
</tr>
<tr style="border-bottom:solid 1px #000000">
<td align="left" colspan="1" rowspan="1" style="border-right:solid 1px #000000" valign="top">Mitochondrial pathogenic findings</td>
<td align="left" colspan="5" rowspan="1" style="border-right:solid 1px #000000" valign="top">
<list id="ajmga61126-list-0002" list-type="bullet"><list-item id="ajmga61126-li-0008"><p>Heteroplasmic 5 kb deletion of the mitochondrial genome encompassing the following genes: <italic>MT‐ATP8, MT‐ATP6, MT‐CO3, MT‐TG, MT‐ND3, MT‐TR, MT‐ND4L, MT‐ND4, MT0TH, MT‐TS2, MT‐TL</italic> and <italic>MT‐ND5</italic>
</p></list-item><list-item id="ajmga61126-li-0009"><p>
<italic>MT‐CYB</italic> p.Gly167Asp (G167D)</p></list-item></list>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig fig-type="Figure" id="ajmga61126-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>Distribution of cases based on mode of inheritance [Color figure can be viewed at <ext-link ext-link-type="uri" xlink:href="http://wileyonlinelibrary.com">http://wileyonlinelibrary.com</ext-link>]</p>
</caption>
<graphic id="nlm-graphic-1" xlink:href="AJMG-179-927-g001"></graphic>
</fig>
<p>Out of AR cases, (60%) had homozygous variants for AR traits, 12 (2.3%) patients were compound heterozygous (Table <xref ref-type="table" rid="ajmga61126-tbl-0006">6</xref>) and three (0.5%) had two compound homozygous variants (a complex allele) in the same gene, which was consistent with their original clinical presentations (Table <xref ref-type="table" rid="ajmga61126-tbl-0007">7</xref>).</p>
<table-wrap id="ajmga61126-tbl-0006" orientation="portrait" position="float" xml:lang="en">
<label>Table 6</label>
<caption>
<p>Patients with compound heterozygous P/LP variants</p>
</caption>
<table frame="hsides" rules="cols">
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="bottom">Patient</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Clinical indication</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Gene</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Disease</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Variant</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">cDNA</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intrahepatic cholestasis, elevated liver enzymes, vitamin D deficiency, and short stature</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CYP2R1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vitamin D25‐hydroxylasedeficiency</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>p.L257SfsX6</p>
<p>p.L89R</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">c.266T&gt;G</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Seizures, hypomyelination, lactic acidosis, cryptorchidism, and a history of intrauterine growth retardation and premature birth</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>ALDH7A1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Epilepsy, pyridoxine‐dependent</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>p.V481E</p>
<p>p.C154R</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>c.1442T&gt;A</p>
<p>c.460T&gt;C</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">4</td>
<td align="left" colspan="1" rowspan="1" valign="top">Possible Joubert syndrome</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CC2D2A</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Joubert syndrome</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>p.L457X</p>
<p>p.E998V</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>c.1370T&gt;A</p>
<p>c.2993 A&gt;T</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">5</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cerebellar ataxia, cerebellar atrophy, and intellectual disability. The family history is significant for two siblings with similar features.</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CWF19L1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Spinocerebellar ataxia 17</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>IVS8‐2A&gt;G</p>
<p>p.V229F</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Arthrogryposis, cerebral palsy, and developmental delay</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>DAG1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Alpha‐dystroglycanopathy</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>p.T531N</p>
<p>p.A98V</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>c.1592 C&gt;A</p>
<p>c.293 C&gt;T</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">7</td>
<td align="left" colspan="1" rowspan="1" valign="top">Elevated liver enzymes, elevated creatine kinase, and motor delay</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>MICU1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">MICU1‐related muscular dystrophy</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>p.Q185X</p>
<p>Partial gene duplication</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>c.553 C&gt;T</p>
<p>NA</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">8</td>
<td align="left" colspan="1" rowspan="1" valign="top">Congenital hydrocephalus and developmental delay</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>B3GALNT2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Muscular dystrophy‐dystroglycanopathy (congenital with brain and eye anomalies, Type A, 11)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>IVS2‐1G&gt;A</p>
<p>p.M75I</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>c.261‐1G&gt;A</p>
<p>c.225G&gt;A</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Slow progressive congenital myopathy</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>PLEC</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Muscular dystrophy, limb‐girdle, Type 2Q</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>p.A2110V</p>
<p>p.R307C</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>c.6329 C&gt;T</p>
<p>c.919 C&gt;T</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">10</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cerebellar ataxia, cerebellar atrophy, and intellectual disability</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CWF19L1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Spinocerebellar ataxia 17</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>IVS8‐2A&gt;G</p>
<p>p.V229F</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>c.850‐2A&gt;G</p>
<p>c.685G&gt;T</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">11</td>
<td align="left" colspan="1" rowspan="1" valign="top">Allergic colitis</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SLC10A2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Primary bile acid</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>p.C106X</p>
<p>p.P251L</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>c.318 C&gt;A</p>
<p>c.752 C&gt;T</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">12</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autism spectrum disorder</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>ANK3</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autism spectrum disorder</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>p.P1489S</p>
<p>p.S2366P</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>c.4465 C&gt;T</p>
<p>c.7096T&gt;C</p>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="ajmga61126-tbl-0007" orientation="portrait" position="float" xml:lang="en">
<label>Table 7</label>
<caption>
<p>Patients with two homozygous variants in the same gene</p>
</caption>
<table frame="hsides" rules="cols">
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="bottom">SN</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Clinical indication</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Gene</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Disease</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Variant</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">cDNA</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Skeletal dysplasia with spine and femur with Swedish key/monkey wrench appearance. Parental consanguinity</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>XYLT1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Desbuquois dysplasia Type 2</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>p.A21GfsX173</p>
<p>IVS7‐3C&gt;T</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>c.62delC</p>
<p>c.1588‐3C&gt;T</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nonimmune hydrops</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>PIEZO1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lymphatic dysplasia with nonimmune hydrops fetalis</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>p.E679X</p>
<p>p.A1496V</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>c.2035 G&gt;T</p>
<p>c.4487 C&gt;T</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pericardial effusion, cardiomegaly, ascites, hepatomegaly, short limbs, hydrops, and echogenic bowel and kidney. Parental consanguinity</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SPTA1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hereditary spherocytosis type 3</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>p.W279X</p>
<p>p.N1934S</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>c.836 G&gt;A</p>
<p>c.5801 A&gt;G</p>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Two patients were homozygous for PV in genes currently only known to be associated with autosomal dominant disorders (Table <xref ref-type="table" rid="ajmga61126-tbl-0008">8</xref>).</p>
<table-wrap id="ajmga61126-tbl-0008" orientation="portrait" position="float" xml:lang="en">
<label>Table 8</label>
<caption>
<p>Patients with homozygous variants in genes typically associated with AD traits</p>
</caption>
<table frame="hsides" rules="cols">
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="bottom">Patient</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Clinical indication</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Gene</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Disease</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Variant</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">cDNA</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Epilepsy, hemiparesis, and migrational anomalies</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SLC1A3</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Episodic ataxia type 6</td>
<td align="left" colspan="1" rowspan="1" valign="top">p.K60Q</td>
<td align="left" colspan="1" rowspan="1" valign="top">c.178 A&gt;C</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Failure to thrive, lung fibrosis, vasculitis, rash, recurrent angiodema, alopecia, and intermittent limb edema</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>TMEM173</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">STING‐associated vasculopathy with onset in infancy</td>
<td align="left" colspan="1" rowspan="1" valign="top">p.R281W</td>
<td align="left" colspan="1" rowspan="1" valign="top">c.841 C&gt;T</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Eleven (2.1%) patients had two molecularly‐identified genetic disorders consistent with their original clinical presentation (Table <xref ref-type="table" rid="ajmga61126-tbl-0009">9</xref>). In addition, 210 variants of uncertain clinical significance (VUS) were reported. These variants were not included in the diagnostic yield calculations.</p>
<table-wrap id="ajmga61126-tbl-0009" orientation="portrait" position="float" xml:lang="en">
<label>Table 9</label>
<caption>
<p>Patients with dual molecular diagnoses</p>
</caption>
<table frame="hsides" rules="cols">
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="bottom">SN</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Inheritance</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Gene</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Disease</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">1</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>AR</p>
<p>AR</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>
<italic>NBEAL2</italic>
</p>
<p>
<italic>DNAH5</italic>
</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>Gray platelet syndrome</p>
<p>Primary Ciliary dyskinesia</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">2</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>AD</p>
<p>AD</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>
<italic>EFTUD2</italic>
</p>
<p>
<italic>NOTCH1</italic>
</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>Mandibulofacial dysostosis</p>
<p>Adams–Oliver syndrome 5</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>AD</p>
<p>AR</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>
<italic>RYR1</italic>
</p>
<p>
<italic>PIEZO1</italic>
</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>RYR1 related disorder (neuromuscular)</p>
<p>Lymphatic dysplasia with nonimmune hydrops fetalis</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">4</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>AR</p>
<p>AD</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>
<italic>LRP5</italic>
</p>
<p>
<italic>PLA2G7</italic>
</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>Van Buchem disease Type 2</p>
<p>Platelet‐activating factor acetylhydrolase deficiency</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">5</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>AD</p>
<p>Mitochondrial</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>
<italic>TPM2</italic>
</p>
<p>
<italic>MT‐CYB</italic>
</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>Arthrogryposis</p>
<p>Leber hereditary optic neuropathy</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">6</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>AD</p>
<p>AR</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>
<italic>SLC1A3</italic>
</p>
<p>
<italic>MCEE</italic>
</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>Episodic ataxia Type 6</p>
<p>Methylmalonic aciduria</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">7</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>AR</p>
<p>AR</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>
<italic>GLE1</italic>
</p>
<p>
<italic>ATM</italic>
</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>Lethal congenital contracture Syndrome‐1</p>
<p>Ataxia telangiectasia</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">8</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>AR</p>
<p>AR</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>
<italic>LAMA2</italic>
</p>
<p>
<italic>TMPRSS4</italic>
</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>Muscular dystrophy, congenital merosin‐deficient</p>
<p>Cerebral atrophy</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">9</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>AR</p>
<p>AR</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>
<italic>NEB</italic>
</p>
<p>
<italic>GALC</italic>
</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>Nemaline myopathy</p>
<p>Krabbe disease</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">10</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>AD</p>
<p>AD (candidate)</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>
<italic>EVC</italic>
</p>
<p>
<italic>TUBA3E</italic>
</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>Ellis–van Creveld syndrome</p>
<p>Global developmental delay, primary microcephaly, lissencephaly, epilepsy (candidate gene)</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">11</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>AR</p>
<p>AR (candidate)</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>
<italic>RPIA</italic>
</p>
<p>
<italic>LAMTOR4</italic>
</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>Ribose‐5‐phosphate isomerase deficiency</p>
<p>Candidate gene</p>
</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="ajmga61126-sec-0015">
<label>3.5</label>
<title>Novel disease gene discovery</title>
<p>Eleven novel candidate genes were reported as potential contributors to the clinical presentation in the respective patients. These were considered as part of the overall diagnostic yield, and results were managed and returned clinically, with appropriate counseling.<list id="ajmga61126-list-0003" list-type="order"><list-item id="ajmga61126-li-0010"><p>
<italic>CLCN3</italic> (p.G327A heterozygous, de novo): Two‐year‐old female who presented with optic atrophy and overweight status.</p></list-item><list-item id="ajmga61126-li-0011"><p>
<italic>HSPB11</italic> (p.L62AfsX14 homozygous, biparental): Two‐year‐old female with lung hypoplasia, polycystic kidneys, and cardiac hypertrophy.</p></list-item><list-item id="ajmga61126-li-0012"><p>
<italic>MACF1</italic> (p.A3721T homozygous, biparental): Deceased female infant with multiple brain abnormalities (severe hydrocephalus and cerebral atrophy).</p></list-item><list-item id="ajmga61126-li-0013"><p>
<italic>XPOT</italic> (p.C877X heterozygous, inheritance unknown): Forty‐nine‐year‐old male with schizophrenia and a family history of dilated cardiomyopathy, psychiatric illness, and early Alzheimer disease. The reported variant was not detected in mother nor in brother with cardiomyopathy.</p></list-item><list-item id="ajmga61126-li-0014"><p>
<italic>GRM5</italic> (AD) (p.S266T heterozygous, de novo): Eleven‐year‐old female with complex vocal and motor tics, learning disability, and obsessive–compulsive disorder.</p></list-item><list-item id="ajmga61126-li-0015"><p>
<italic>SCHIP1</italic> (p.R452* homozygous): 4‐year‐old male of consanguineous parents with a history of hypotonia, macrocephaly, developmental delay, and abnormal MRI findings. This homozygous nonsense variant segregated in the proband's two similarly affected sisters.</p></list-item><list-item id="ajmga61126-li-0016"><p>
<italic>TUBA3E</italic> (p.A150V and p.R215C compound heterozygous): Male with bilateral limb reduction, horseshoe kidney, undescended testes, and neuronal migration defect on brain MRI</p></list-item><list-item id="ajmga61126-li-0017"><p>
<italic>UNC13A</italic> (p.V1619G homozygous, biparental): Male child with epileptic encephalopathy with intractable seizures and global developmental delay. The family history is significant for parental consanguinity.</p></list-item><list-item id="ajmga61126-li-0018"><p>
<italic>LAMTOR4</italic> (p.Q90GfsX42 homozygous, biparental): Female child with Microcephaly, developmental delay, hypertonia, cortical hypomyelination, abnormal white matter, and dysmorphic features.</p></list-item><list-item id="ajmga61126-li-0019"><p>
<italic>MAP4K4</italic> (p.S604T homozygous, biparental): Male child with microcephaly, speech delay, facial dysmorphism, developmental delay, and aggressive behavior. Family history is significant for a similarly affected sister who is also homozygous for this variant. The proband's two unaffected brothers were heterozygous for this variant.</p></list-item><list-item id="ajmga61126-li-0020"><p>
<italic>GALNT11</italic> (p.R384X Homozygous biparental) Male child withdisproportionate limb shortening, facial dysmorphism, short stature, failure to thrive</p></list-item></list>
</p>
</sec>
<sec id="ajmga61126-sec-0016">
<label>3.6</label>
<title>ACMG secondary findings</title>
<p>Fifteen percent of patients/families opted to receive secondary findings. Secondary findings were reported in three probands (3.9% of those who elected to receive these findings) in our cohort, and was performed per to the American College of Medical Genetics and Genomics (ACMG) recommendations (Green et al., <xref ref-type="ref" rid="ajmga61126-bib-0008">2013</xref>). One patient had an autosomal dominant heterozygous pathogenic variant (p.E22K) in the <italic>MYL2</italic> gene associated with hypertrophic cardiomyopathy requiring medical action; one patient had an autosomal dominant heterozygous pathogenic variant (p.R248Q) in the <italic>TP53</italic> gene for Li–Fraumeni syndrome; and one female patient had an autosomal dominant heterozygous pathogenic variant (c.4136_4137delCT) in the <italic>BRCA1</italic> gene. The latter two patients were referred to a cancer center for further management.</p>
</sec>
<sec id="ajmga61126-sec-0017">
<label>3.7</label>
<title>CES reanalysis</title>
<p>CES was negative (nondiagnostic) for 27% of patients (136/509), with no reportable variants and/or where the reported variant did not explain the proband's phenotype. Nevertheless, reanalysis by CES revealed diagnostic results in 34 patients, corresponding to 25% of reanalysis cases. Supporting Information Table <xref ref-type="supplementary-material" rid="ajmga61126-supitem-0001">S4</xref>.</p>
</sec>
<sec id="ajmga61126-sec-0018">
<label>3.8</label>
<title>CES shortens time to diagnosis</title>
<p>The average time to a definitive diagnosis from the patient's first visit to a genetic clinic was significantly shorter (<italic>p</italic> ≤ 0.0001) for patients who had CES as a first‐tier test (3 months; 173/246 positive cases) compared to those who had other diagnostic workups first, and who then later reflexed to CES (18 months; 73/246 positive cases). An early diagnosis can inform medical management and potentially improve patient quality of life. Supporting Information Table <xref ref-type="supplementary-material" rid="ajmga61126-supitem-0001">S5</xref> summarizes treatable diagnoses identified by CES. It is also important for defining patient prognoses for families and may enable a patient to participate in clinical trials earlier. Finally, earlier diagnoses can also lead to earlier “cascade” or familial testing. Supporting Information Table <xref ref-type="supplementary-material" rid="ajmga61126-supitem-0001">S5</xref>.</p>
</sec>
</sec>
<sec id="ajmga61126-sec-0019">
<label>4</label>
<title>DISCUSSION</title>
<p>We previously reported that the diagnostic yield of CES was 60% in 149 patients from Qatar. In this larger study, as we continually enrolled a new cohort of 509 CES with rare and diverse disorders, the overall diagnostic yield of CES was 48.3% (<italic>n</italic> = 246). The lower diagnostic rate in this current study may be related to the strict use of ACMG guidelines for variant classification, which was not used in the first cohort, but may also involve other factors. Within our cohort, the highest diagnostic rate (64%) was observed for patients with neuromuscular disorders.</p>
<p>As expected, autosomal recessive variants accounted for the majority of identified causative variants. Consistent with our prior published experience, we note that this pattern extends to genes that had only been linked to human diseases in the autosomal dominant mode of inheritance (Monies, Abouelhoda, et al., <xref ref-type="ref" rid="ajmga61126-bib-0009">2017</xref>). In addition, enhanced autozygosity facilitated the co‐inheritance of more than one homozygous disease‐causing variant with resulting dual molecular diagnoses in several cases. The apparently lower incidence of these “multilocus” phenotypes compared to a previous estimate is likely related to our strict use of ACMG guidelines to call pathogenic variants. Indeed, our estimate is nearly identical to another study involving a comparable Middle Easter population that applied to the same criteria (Monies et al., <xref ref-type="ref" rid="ajmga61126-bib-0010">2017</xref>).</p>
<p>Eleven novel candidate genes were reported in this cohort of patients. These genes had not been reported in associated with human disease or the published data to support human disease association may not yet be definitive. While supporting data for the candidacy of these genes (e.g., model organism data, intolerance of the gene to sequence variation, tissue or developmental timing of expression, or knowledge of the gene function and pathway analysis) are suggestive, we emphasize that these remain candidates pending future confirmation through the reporting of similarly affected patients.</p>
<p>Others have noted the importance of reanalyzing CES to improve the diagnostic rate (Ewans et al., <xref ref-type="ref" rid="ajmga61126-bib-0006">2018</xref>; Shamseldin et al., <xref ref-type="ref" rid="ajmga61126-bib-0012">2017</xref>; Wright et al., <xref ref-type="ref" rid="ajmga61126-bib-0014">2018</xref>). However, it is likely that CES will never reach 100% diagnostic rate even in patients with a clearly genetic etiology because of technical limitations. Despite the encouraging early results from WGS in these “negative” cases, the full potential of WGS in patients who could not be diagnosed by CES remains to be seen (Alfares et al., <xref ref-type="ref" rid="ajmga61126-bib-0002">2018</xref>). Testing other tissue sources as well as additional modalities at the RNA, epigenetic, and multilocus levels will likely be necessary to resolve an even higher proportion of cases.</p>
<p>The value of an early diagnosis for most patients is to improve management and quality of life. It is also of critical importance to the patient's family as defining a diagnosis allows specific prognostic predictions, connecting to other families and patient support groups. Although there are limited treatments available for many patients, an earlier diagnosis may allow these patients to participate in available clinical trials.</p>
<p>A limitation of interpretation of variants found by CES in ME patients has been the lack of reliable control cohort data, such as estimating the minor allele frequencies of variants in healthy individuals from the Middle East. However, this obstacle can be overcome by establishing databases of normal variants and disease‐causing variants in Arab population. Examples of current efforts in Qatar and the Arabian gulf region include establishing the Qatar Genome Program (QGP) and the Saudi Human Genome Program (SHGP).</p>
</sec>
<sec id="ajmga61126-sec-0020">
<label>5</label>
<title>CONCLUSIONS</title>
<p>CES is a powerful tool for ending the diagnostic odyssey in cases with an unsolved/undiagnosed genetic disorder after traditional molecular diagnostic approaches have been exhausted, and may even be better deployed as a first step approach. CES has the potential to identify potential novel candidate genes and variants in multiple genes (dual diagnoses) resulting in a more complex disease phenotype. Our results support the adoption of CES as routine clinical diagnostic services locally in Qatar and perhaps to other populations with similar characteristics.</p>
</sec>
<sec id="ajmga61126-sec-0022" sec-type="COI-statement">
<title>CONFLICT OF INTEREST</title>
<p>The authors declare that there are no conflict of interest.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material content-type="local-data" id="ajmga61126-supitem-0001">
<caption>
<p>
<bold>Supplementary Table 1</bold> Novel LP variants in diagnostic cases (VUS in novel candidate genes are in bold)</p>
<p>
<bold>Supplementary Table 2</bold>: Previously reported P/LP variants in diagnostic cases</p>
<p>
<bold>Supplementary Table 3</bold>: Detailed clinical features in diagnostic cases</p>
<p>
<bold>Supplementary Table 4</bold>: Detailed CES reanalysis data</p>
<p>
<bold>Supplementary Table 5</bold>: Directly treatable disorders identified by CES</p>
<p>
<bold>Supplementary Table 6</bold>: List of cases with atypical presentation, thus broadening the phenotypic spectrum of the respective disorders</p>
</caption>
<media xlink:href="AJMG-179-927-s001.docx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<ack id="ajmga61126-sec-0021">
<title>ACKNOWLEDGMENTS</title>
<p>The authors would like to thank patients and their families described in this article, the healthcare providers who were involved in their patient care and extend our thanks to Mr. Patricio Santos Ayroso and Ms. Magi Martin for their administrative support. The authors also acknowledge the work of the clinical exome team at GeneDx.</p>
</ack>
<ref-list content-type="cited-references" id="ajmga61126-bibl-0001">
<title>REFERENCES</title>
<ref id="ajmga61126-bib-0001">
<mixed-citation id="ajmga61126-cit-0001" publication-type="journal">
<string-name>
<surname>Alfares</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Alfadhel</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Wani</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Alsahli</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Alluhaydan</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Al Mutairi</surname>, <given-names>F.</given-names>
</string-name>, … <string-name>
<surname>Zada</surname>, <given-names>A. A. P.</given-names>
</string-name> (<year>2017</year>). <article-title>A multicenter clinical exome study in unselected cohorts from a consanguineous population of Saudi Arabia demonstrated a high diagnostic yield</article-title>. <source xml:lang="en"/>Molecular Genetics and Metabolism, <volume>121</volume>(<issue>2</issue>), <fpage>91</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymgme.2017.04.002</pub-id>
<pub-id pub-id-type="pmid">28454995</pub-id></mixed-citation>
</ref>
<ref id="ajmga61126-bib-0002">
<mixed-citation id="ajmga61126-cit-0002" publication-type="journal">
<string-name>
<surname>Alfares</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Aloraini</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Al Subaie</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Alissa</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Al Qudsi</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Alahmad</surname>, <given-names>A.</given-names>
</string-name>, … <string-name>
<surname>Alfadhel</surname>, <given-names>M.</given-names>
</string-name> (<year>2018</year>). <article-title>Whole‐genome sequencing offers additional but limited clinical utility compared with reanalysis of whole‐exome sequencing</article-title>. <source xml:lang="en"/>Genetics in Medicine, <volume>20</volume>, <fpage>1328</fpage>–<lpage>1333</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2018.41</pub-id>
<pub-id pub-id-type="pmid">29565419</pub-id></mixed-citation>
</ref>
<ref id="ajmga61126-bib-0003">
<mixed-citation id="ajmga61126-cit-0003" publication-type="journal">
<string-name>
<surname>Al‐Shamsi</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Hertecant</surname>, <given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Souid</surname>, <given-names>A. K.</given-names>
</string-name>, &amp; <string-name>
<surname>Al‐Jasmi</surname>, <given-names>F. A.</given-names>
</string-name> (<year>2016</year>). <article-title>Whole exome sequencing diagnosis of inborn errors of metabolism and other disorders in United Arab Emirates</article-title>. <source xml:lang="en"/>Orphanet Journal of Rare Diseases, <volume>11</volume>(<issue>1</issue>), <fpage>94</fpage>
<pub-id pub-id-type="doi">10.1186/s13023-016-0474-3</pub-id>
<pub-id pub-id-type="pmid">27391121</pub-id></mixed-citation>
</ref>
<ref id="ajmga61126-bib-0004">
<mixed-citation id="ajmga61126-cit-0004" publication-type="journal">
<string-name>
<surname>Anazi</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Maddirevula</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Faqeih</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Alsedairy</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Alzahrani</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Shamseldin</surname>, <given-names>H. E.</given-names>
</string-name>, … <string-name>
<surname>Alkuraya</surname>, <given-names>F. S.</given-names>
</string-name> (<year>2017</year>). <article-title>Clinical genomics expands the morbid genome of intellectual disability and offers a high diagnostic yield</article-title>. <source xml:lang="en"/>Molecular Psychiatry, <volume>22</volume>(<issue>4</issue>), <fpage>615</fpage>–<lpage>624</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2016.113</pub-id>
<pub-id pub-id-type="pmid">27431290</pub-id></mixed-citation>
</ref>
<ref id="ajmga61126-bib-0005">
<mixed-citation id="ajmga61126-cit-0005" publication-type="journal">
<string-name>
<surname>Charng</surname>, <given-names>W.‐L.</given-names>
</string-name>, <string-name>
<surname>Karaca</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Akdemir</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Zeynep</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Tomasz</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Mehmed</surname>, <given-names>M.</given-names>
</string-name>, … <string-name>
<surname>Lupski</surname>, <given-names>J. R.</given-names>
</string-name> (<year>2016</year>). <article-title>Exome sequencing in mostly consanguineous Arab families with neurologic disease provides a high potential molecular diagnosis rate</article-title>. <source xml:lang="en"/>BMC Medical Genomics, <volume>9</volume>, <fpage>42</fpage>
<pub-id pub-id-type="doi">10.1186/s12920-016-0208-3</pub-id>
<pub-id pub-id-type="pmid">27435318</pub-id></mixed-citation>
</ref>
<ref id="ajmga61126-bib-0006">
<mixed-citation id="ajmga61126-cit-0006" publication-type="journal">
<string-name>
<surname>Ewans</surname>, <given-names>L. J.</given-names>
</string-name>, <string-name>
<surname>Schofield</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Shrestha</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Gayevskiy</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Ying</surname>, <given-names>K.</given-names>
</string-name>, … <string-name>
<surname>Roscioli</surname>, <given-names>T.</given-names>
</string-name> (<year>2018</year>). <article-title>Whole‐exome sequencing reanalysis at 12 months boosts diagnosis and is cost‐effective when applied early in Mendelian disorders</article-title>. <source xml:lang="en"/>Genetics in Medicine, <volume>20</volume>, <fpage>1564</fpage>–<lpage>1574</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2018.39</pub-id>
<pub-id pub-id-type="pmid">29595814</pub-id></mixed-citation>
</ref>
<ref id="ajmga61126-bib-0007">
<mixed-citation id="ajmga61126-cit-0007" publication-type="journal">
<string-name>
<surname>Fattahi</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Kalhor</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Fadaee</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Vazehan</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Parsimehr</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Abolhassani</surname>, <given-names>A.</given-names>
</string-name>, … <string-name>
<surname>Najmabadi</surname>, <given-names>H.</given-names>
</string-name> (<year>2016</year>). <article-title>Improved diagnostic yield of neuromuscular disorders applying clinical exome sequencing in patients arising from a consanguineous population</article-title>. <source xml:lang="en"/>Clinical Genetics, <volume>91</volume>, <fpage>386</fpage>–<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1111/cge.12810</pub-id>
<pub-id pub-id-type="pmid">27234031</pub-id></mixed-citation>
</ref>
<ref id="ajmga61126-bib-0008">
<mixed-citation id="ajmga61126-cit-0008" publication-type="journal">
<string-name>
<surname>Green</surname>, <given-names>R. C.</given-names>
</string-name>, <string-name>
<surname>Berg</surname>, <given-names>J. S.</given-names>
</string-name>, <string-name>
<surname>Grody</surname>, <given-names>W. W.</given-names>
</string-name>, <string-name>
<surname>Kalia</surname>, <given-names>S. S.</given-names>
</string-name>, <string-name>
<surname>Korf</surname>, <given-names>B. R.</given-names>
</string-name>, <string-name>
<surname>Martin</surname>, <given-names>C. L.</given-names>
</string-name>, … <string-name>
<surname>Ormond</surname>, <given-names>K. E.</given-names>
</string-name> (<year>2013</year>). <article-title>ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing</article-title>. <source xml:lang="en"/>Genetics in Medicine, <volume>15</volume>(<issue>7</issue>), <fpage>565</fpage>–<lpage>574</lpage>.<pub-id pub-id-type="pmid">23788249</pub-id></mixed-citation>
</ref>
<ref id="ajmga61126-bib-0009">
<mixed-citation id="ajmga61126-cit-0009" publication-type="journal">
<string-name>
<surname>Monies</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Abouelhoda</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>AlSayed</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Alhassnan</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Alotaibi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Kayyali</surname>, <given-names>H.</given-names>
</string-name>, … <string-name>
<surname>Alkuraya</surname>, <given-names>F. S.</given-names>
</string-name> (<year>2017</year>). <article-title>The landscape of genetic diseases in Saudi Arabia based on the first 1000 diagnostic panels and exomes</article-title>. <source xml:lang="en"/>Human Genetics, <volume>136</volume>(<issue>8</issue>), <fpage>921</fpage>–<lpage>939</lpage>. <pub-id pub-id-type="doi">10.1007/s00439-017-1821-8</pub-id>
<pub-id pub-id-type="pmid">28600779</pub-id></mixed-citation>
</ref>
<ref id="ajmga61126-bib-0010">
<mixed-citation id="ajmga61126-cit-0010" publication-type="journal">
<string-name>
<surname>Monies</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Maddirevula</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Kurdi</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Alanazy</surname>, <given-names>M. H.</given-names>
</string-name>, <string-name>
<surname>Alkhalidi</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Al‐Owain</surname>, <given-names>M.</given-names>
</string-name>, … <string-name>
<surname>Alkuraya</surname>, <given-names>F. S.</given-names>
</string-name> (<year>2017</year>). <article-title>Autozygosity reveals recessive mutations and novel mechanisms in dominant genes: Implications in variant interpretation</article-title>. <source xml:lang="en"/>Genetics in Medicine, <volume>19</volume>(<issue>10</issue>), <fpage>1144</fpage>–<lpage>1150</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2017.22</pub-id>
<pub-id pub-id-type="pmid">28383543</pub-id></mixed-citation>
</ref>
<ref id="ajmga61126-bib-1011">
<mixed-citation id="ajmga61126-cit-1011" publication-type="journal">
<string-name>
<surname>Richards</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Aziz</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Bale</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Bick</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Das</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Gastier‐Foster</surname>, <given-names>J.</given-names>
</string-name>, … <string-name>
<surname>Rehm</surname>, <given-names>H. L.</given-names>
</string-name>, <collab collab-type="authors">ACMG Laboratory Quality Assurance Committee</collab>
(<year>2015</year>). <article-title>Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>. <source xml:lang="en"/>Genetics in Medicine, <volume>17</volume>(<issue>5</issue>), <fpage>405</fpage>–<lpage>424</lpage>.<pub-id pub-id-type="pmid">25741868</pub-id></mixed-citation>
</ref>
<ref id="ajmga61126-bib-0011">
<mixed-citation id="ajmga61126-cit-0011" publication-type="journal">
<string-name>
<surname>Retterer</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Scuffins</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Pineda‐Alvarez</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Stafford</surname>, <given-names>A.</given-names>
</string-name>, … <string-name>
<surname>Haverfield</surname>, <given-names>E.</given-names>
</string-name> (<year>2015</year>). <article-title>Assessing copy number from exome sequencing and exome array CGH based on CNV spectrum in a large clinical cohort</article-title>. <source xml:lang="en"/>Genetics in Medicine, <volume>17</volume>(<issue>8</issue>), <fpage>623</fpage>–<lpage>629</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2014.160</pub-id>
<pub-id pub-id-type="pmid">25356966</pub-id></mixed-citation>
</ref>
<ref id="ajmga61126-bib-0012">
<mixed-citation id="ajmga61126-cit-0012" publication-type="journal">
<string-name>
<surname>Shamseldin</surname>, <given-names>H. E.</given-names>
</string-name>, <string-name>
<surname>Maddirevula</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Faqeih</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Ibrahim</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Hashem</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Shaheen</surname>, <given-names>R.</given-names>
</string-name>, &amp; <string-name>
<surname>Alkuraya</surname>, <given-names>F. S.</given-names>
</string-name> (<year>2017</year>). <article-title>Increasing the sensitivity of clinical exome sequencing through improved filtration strategy</article-title>. <source xml:lang="en"/>Genetics in Medicine, <volume>19</volume>(<issue>5</issue>), <fpage>593</fpage>–<lpage>598</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2016.155</pub-id>
<pub-id pub-id-type="pmid">27711071</pub-id></mixed-citation>
</ref>
<ref id="ajmga61126-bib-0013">
<mixed-citation id="ajmga61126-cit-0013" publication-type="journal">
<string-name>
<surname>Stark</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Schofield</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Martyn</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Rynehart</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Shrestha</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Alam</surname>, <given-names>K.</given-names>
</string-name>, … <string-name>
<surname>White</surname>, <given-names>S. M.</given-names>
</string-name> (<year>2018</year>). <article-title>Does genomic sequencing early in the diagnostic trajectory make a difference? A follow‐up study of clinical outcomes and cost‐effectiveness</article-title>. <source xml:lang="en"/>Genetics in Medicine, <volume>21</volume>, <fpage>173</fpage>–<lpage>180</lpage>. <pub-id pub-id-type="doi">10.1038/s41436-018-0006-8</pub-id>
<pub-id pub-id-type="pmid">29765138</pub-id></mixed-citation>
</ref>
<ref id="ajmga61126-bib-0014">
<mixed-citation id="ajmga61126-cit-0014" publication-type="journal">
<string-name>
<surname>Wright</surname>, <given-names>C. F.</given-names>
</string-name>, <string-name>
<surname>McRae</surname>, <given-names>J. F.</given-names>
</string-name>, <string-name>
<surname>Clayton</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Gallone</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Aitken</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>FitzGerald</surname>, <given-names>T. W.</given-names>
</string-name>, … <string-name>
<surname>Firth</surname>, <given-names>H. V.</given-names>
</string-name> (<year>2018</year>). <article-title>Making new genetic diagnoses with old data: Iterative reanalysis and reporting from genome‐wide data in 1,133 families with developmental disorders</article-title>. <source xml:lang="en"/>Genetics in Medicine, <volume>20</volume>, <fpage>1216</fpage>–<lpage>1223</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2017.246</pub-id>
<pub-id pub-id-type="pmid">29323667</pub-id></mixed-citation>
</ref>
<ref id="ajmga61126-bib-0015">
<mixed-citation id="ajmga61126-cit-0015" publication-type="journal">
<string-name>
<surname>Yavarna</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Al‐Dewik</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Al‐Mureikhi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Ali</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Al‐Mesaifri</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Mahmoud</surname>, <given-names>L.</given-names>
</string-name>, … <string-name>
<surname>Ben‐Omran</surname>, <given-names>T.</given-names>
</string-name> (<year>2015</year>). <article-title>High diagnostic yield of clinical exome sequencing in middle eastern patients with Mendelian disorders</article-title>. <source xml:lang="en"/>Human Genetics, <volume>134</volume>(<issue>9</issue>), <fpage>967</fpage>–<lpage>980</lpage>. <pub-id pub-id-type="doi">10.1007/s00439-015-1575-0</pub-id>
<pub-id pub-id-type="pmid">26077850</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>